IREN pricing strength supports revenue per MW but does not yet resolve execution and dilution risks

What happened

A recent article highlights IREN's rising revenue per MW, stronger pricing, and customer prepayments as improving returns on expanding capacity. The DeepValue master report acknowledges that recent contracts have exceeded $20 million per MW with discussions around $25 million, indicating genuine pricing power. However, the company's reported financials still show deep operating losses, heavy stock-based compensation, and rapid share dilution, with FY2026 revenue dominated by Bitcoin mining and AI cloud revenue only $128.8 million. The stock near $40 already prices in smooth conversion of contracted backlog to recognized revenue, which remains contingent on Microsoft acceptance of Horizons 2-4 and signed 2027 contracts. Until those operational milestones are confirmed, the pricing narrative alone does not justify the current valuation.

Implication

For investors, the key is to separate commercial momentum from per-share economics. Pricing strength and prepayments reduce financing risk, but they do not eliminate execution risk: Horizons 2-4 must be accepted by early Q2 2027, and 2027 capacity must be pre-sold with disclosed terms to avoid another large equity raise. The stock currently trades above the report's attractive entry of $34 and near the trim level of $49, with limited margin of safety given negative earnings and high EV/EBITDA. A disciplined approach would wait for either a pullback toward $34 or concrete evidence of capacity acceptance and new signed contracts before adding exposure. Conversely, if delay credits or stalled backlog conversion appear, the thesis weakens and position sizes should be reduced.

Thesis delta

No material thesis change. The article adds color on pricing and prepayments, which were already reflected in the DeepValue report's bull scenario and recent management disclosures. It does not alter the central WAIT rating, which hinges on converting contracted ARR into recognized revenue and avoiding dilutive financing. The balance of evidence still favors waiting for operational proof rather than chasing the pricing narrative.